Post COVID 19 Treatment Designed to Mitigate Lung Damage & Systemic Inflammation

In an effort to help mitigate residual pulmonary injury and long term lung damage caused by the SARS COVID 19 virus, the GARM Clinic is pleased to announce the latest treatment protocol for post COVID 19 infections.

In addition to potential long term lung damage, many patients report residual exhaustion and "brain fog" several weeks to months after the resolution of the viral infection. The list doesn't end here. Read More.

There may be hope for resolution of some of these issues!

Because the safety and efficacy of this particular treatment protocol has been established at the GARM Clinic over the past six years in COPD patients, we can say with confidence the post COVID 19 treatment protocol offered by the GARM Clinic poses a very low risk to the patient, as well as potential healing benefits. In our experience, there have been no adverse events reported by our patients directly related to any regenerative medicine treatment provided by the GARM Clinic, including those for COPD, and most recently those for post COVID 19 mitigation.



The COVID-19 Viral Global Pandemic has left many with post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality, notes Robert W. Alexander, M.D., a key member of the GARM Physician Team.[1]

Even with the successful resolution of COVID 19 symptoms, lung stress may still exist, progressing towards a chronic situation, which may negatively affect energy levels, cognition, etc. Many recovered patients have presented with mild to severe lung impairment as a result of the viral attack on the alveolar and interstitial lung tissues. This may result in clinically significant impairment of pulmonary function; and it appears to be a permanent finding as a direct result of the interstitial lung damage that resulted from the inflammatory changes caused by the COVID-19 infection, as presented by Robert W. Alexander, M.D.[1], in a recent publication demonstrating potential value for treatments that may mitigate damage to the alveoli, and possibly restore more normal function to the lungs. Keep Reading.